Literature DB >> 22473512

RAS blockade, hyperkalemia and AKI--look and you will find.

Robert D Toto1.   

Abstract

Aliskiren combined with other inhibitors of the renin–angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22473512     DOI： 10.1038/nrneph.2012.62

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  8 in total

Review 1.  Regulation of the epithelial sodium channel by accessory proteins.

Authors:  Kelly Gormley; Yanbin Dong; Giuseppe A Sagnella
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

2.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Authors:  Suzanne Oparil; Steven A Yarows; Samir Patel; Hui Fang; Jack Zhang; Andrew Satlin
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

Review 3.  Treatment and landmark clinical trials for renoprotection.

Authors:  Rose Z W Ting; Andrea O Y Luk; Juliana C N Chan
Journal:  Contrib Nephrol       Date:  2011-06-09       Impact factor: 1.580

4.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

5.  Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis.

Authors:  R D Toto; H C Mitchell; H C Lee; C Milam; W A Pettinger
Journal:  Ann Intern Med       Date:  1991-10-01       Impact factor: 25.391

6.  Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

Authors:  Uzma F Mehdi; Beverley Adams-Huet; Philip Raskin; Gloria L Vega; Robert D Toto
Journal:  J Am Soc Nephrol       Date:  2009-11-19       Impact factor: 10.121

7.  Effect of telmisartan on renal outcomes: a randomized trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Leanne Dyal; Matthew J McQueen; Helmut Schumacher; Janice Pogue; Xingyu Wang; Jeffrey L Probstfield; Alvaro Avezum; Ernesto Cardona-Munoz; Gilles R Dagenais; Rafael Diaz; George Fodor; Jean M Maillon; Lars Rydén; Cheuk M Yu; Koon K Teo; Salim Yusuf
Journal:  Ann Intern Med       Date:  2009-05-18       Impact factor: 25.391

Review 8.  The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis.

Authors:  Ziv Harel; Cameron Gilbert; Ron Wald; Chaim Bell; Jeff Perl; David Juurlink; Joseph Beyene; Prakesh S Shah
Journal:  BMJ       Date:  2012-01-09
  8 in total
  2 in total

Review 1.  Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis.

Authors:  Shufang Fu; Xin Wen; Fei Han; Yin Long; Gaosi Xu
Journal:  Oncotarget       Date:  2017-07-19

2.  Diabetic kidney disease: a report from an ADA Consensus Conference.

Authors:  Katherine R Tuttle; George L Bakris; Rudolf W Bilous; Jane L Chiang; Ian H de Boer; Jordi Goldstein-Fuchs; Irl B Hirsch; Kamyar Kalantar-Zadeh; Andrew S Narva; Sankar D Navaneethan; Joshua J Neumiller; Uptal D Patel; Robert E Ratner; Adam T Whaley-Connell; Mark E Molitch
Journal:  Diabetes Care       Date:  2014-10       Impact factor: 19.112
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.